|
Synonyms: ALXN-1720 | ALXN1720 | CON-9978 | Klygefa® | TPP-2511
Compound class:
Antibody
Comment: Gefurulimab (ALXN1720) is a bispecific VHH nanobody that binds complement component C5 (in the terminal complement cascade) and serum albumin [1]. It is designed to block enzymatic cleavage of C5 (into biologically active C5a and C5b fragments), and reduce inflammation. Binding to serum albumin extends the agent's systemic half-life and therapeutic window.
|
Classification ![]() |
|
| Compound class | Antibody |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11982 | gefurulimab |
Synonyms ![]() |
| ALXN-1720 | ALXN1720 | CON-9978 | Klygefa® | TPP-2511 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 1253 |
| Other databases | |
| Search PubMed clinical trials | gefurulimab |
| Search PubMed titles | gefurulimab |
| Search PubMed titles/abstracts | gefurulimab |